ArticleDermatologic therapy2020
Biologics for psoriasis in COVID-19 era: What do we know?
Article in Dermatologic therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: A systematic review and meta-analysis.Frontiers in immunology · 2022Pooled it
- Cutaneous manifestations and considerations in COVID-19 pandemic: A systematic review.Dermatologic therapy · 2020Pooled it
- The Relationship Between Psoriasis, COVID-19 Infection and Vaccination During Treatment of Patients.Advances in experimental medicine and biology · 2023Article
- The Impact of Immune-Modulating Treatments for Dermatological Diseases on the Risk of Infection with SARS-CoV-2 and Outcomes Associated with COVID-19 Illness.Current dermatology reports · 2023Review
- Skin Manifestations in Psoriatic and HS Patients in Treatment with Biologicals during the COVID-19 Pandemic.Journal of clinical medicine · 2021Review
- Use of Monoclonal Antibodies Therapy for Treatment of Mild to Moderate COVID-19 in 4 Patients with Rheumatologic Disorders.Medical science monitor : international medical journal of experimental and clinical research · 2021Article
- What Has Changed in the Treatment of Psoriatic Arthritis After COVID-19?The Eurasian journal of medicine · 2021Review
- Calming the inflammatory storm in severe COVID-19 infections: Role of biologics- A narrative review.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2021Review
- Literature Overview of the IL-17 Inhibition from Psoriasis to COVID-19.Journal of inflammation research · 2021Review
- Severe COVID-19 outcomes in patients with psoriasis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2020Article
- Psoriasis and COVID-19: A narrative review with treatment considerations.Dermatologic therapy · 2020Review
- Psoriasis Management During the COVID-19 Pandemic: Recommendations by SIG Psoriasis (IADVL Academy).Indian dermatology online journalArticle
- Impact of the COVID-19 pandemic on the course and management of chronic inflammatory immune-mediated skin diseases: What's the evidence?Clinics in dermatologyReview
- Use of Immunosuppressants/Immunomodulators in Autoimmune/Inflammatory Dermatologic Diseases during COVID-19 Pandemic-General Recommendation Based on Available Evidence.Indian dermatology online journalArticle
Corrections and comments
- Comment on
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.